electroCore, Inc. (the "Company"), (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
electroCore, Inc. (the "Company"), (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,191,953 to the Company, relating to the treatment of stroke symptoms.
The newly issued patent is related to methods for treating the acute symptoms of stroke or transient ischemic attack (TIA), a temporary period of symptoms similar to those of a stroke, according to a treatment paradigm based on the application of a transcutaneous, non-invasive electrical impulse or stimulation.
This newly allowed patent is owned by the Company and reinforces development efforts associated with certain investigator-initiated trials in the area of stroke which is the second highest cause of death and third leading cause of disability globally. Earlier this year, the Company announced full enrollment of the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke.
"We are pleased with this latest patent issuance relating to another potential important use of electroCore's non-invasive approach to treating patients with vagus nerve stimulation that has devastating impacts on people's lives," commented JP Errico, a founder, board member and investor of the Company, who was also a co-inventor of the new patent. "Every year, roughly 15 million people worldwide suffer strokes, and our non-invasive vagus nerve stimulator technology may be an effective acute treatment to reduce the damaging effects to the brains of these patients. With ongoing investigator-initiated trials in stroke, and our newly issued patent, we look forward to understanding nVNS's potential role in the treatment paradigm for stroke patients worldwide."
Recent Comments